Literature DB >> 25550128

Blinatumomab approved for rare leukemia.

Kate Traynor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25550128     DOI： 10.2146/news150005

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  3 in total

1.  Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.

Authors:  Nicole C Smits; Charles L Sentman
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

Review 2.  Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.

Authors:  Delong Liu; Juanjuan Zhao; Yongping Song; Xiaofeng Luo; Ting Yang
Journal:  J Hematol Oncol       Date:  2019-02-08       Impact factor: 17.388

Review 3.  Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.

Authors:  Jingjing Wu; Jiaping Fu; Mingzhi Zhang; Delong Liu
Journal:  J Hematol Oncol       Date:  2015-09-04       Impact factor: 17.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.